Clinical evaluation and applications of the Amplicor HBV Monitor(TM) test, a quantitative HBV DNA PCR assay

G. Gerken, J. Gomes, P. Lampertico, M. Colombo, T. Rothaar, M. Trippler, G. Colucci

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Viral load has emerged recently as a reliable marker of disease progression and therapeutic efficacy in chronic infections, including AIDS and hepatitis C. The clinical management of type B hepatitis could also be improved by monitoring viremia levels in patients with chronic liver disease undergoing anti-viral treatment. To address this question we evaluated the performance of a newly developed, quantitative PCR assay (Amplicor HBV Monitor(TM) test, Roche Diagnostic Systems) in the assessment of viremia changes over time in a group of 45 patients with chronic active hepatitis (CAH) who received interferon treatment. Of the 45 patients, 14 were HBsAg and anti-HBeAg positive and 31 HBsAg, HBeAg positive. Follow-up extended up to 24 months. An average of ten samples per patient were analyzed for levels of ALT, IgM anti-HBc (Abbott Laboratories), HBV DNA by in-house dot-blot hybridization and hybridization-capture assays (HBV-DNA hybrid capture kit, Murex Diagnostics) and by Amplicor HBV Monitor. A sustained biochemical response was observed at the end of treatment in 12 HBeAg-positive and in seven anti-HBeAg positive patients. This was accompanied by the disappearance of HBeAg and of HBV DNA (hybridization assays) in all cases and by the clearance of IgM anti-HBc in 70% of the cases. Viremia (quantitative PCR assay) became undetectable only in 25-30% of cases and was associated with the loss of HBsAg. A good correlation was observed between the time course of IgM anti-HBc, quantitative PCR and dot-blot hybridization although the latter missed 33% of viremic samples. Together, these results indicate that the Amplicor HBV Monitor test is a robust and standardized assay for quantifying HBV viremia levels in the range from 102 to 107 copies/ml. Compared to other current markers, viral load may provide additional clinical information by predicting long term virologic response and HBsAg clearance in patients with normal ALT at the end of interferon therapy. Copyright (C) 1998 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)155-165
Number of pages11
JournalJournal of Virological Methods
Volume74
Issue number2
DOIs
Publication statusPublished - Oct 1998

Fingerprint

Hepatitis B e Antigens
Viremia
Hepatitis B Surface Antigens
Polymerase Chain Reaction
DNA
Viral Load
Interferons
Therapeutics
Chronic Hepatitis
Hepatitis C
Hepatitis B
Routine Diagnostic Tests
Disease Progression
Liver Diseases
Acquired Immunodeficiency Syndrome
Chronic Disease
Infection
anti-IgM

Keywords

  • HBV DNA
  • PCR
  • Quantitation
  • Viremia

ASJC Scopus subject areas

  • Virology

Cite this

Clinical evaluation and applications of the Amplicor HBV Monitor(TM) test, a quantitative HBV DNA PCR assay. / Gerken, G.; Gomes, J.; Lampertico, P.; Colombo, M.; Rothaar, T.; Trippler, M.; Colucci, G.

In: Journal of Virological Methods, Vol. 74, No. 2, 10.1998, p. 155-165.

Research output: Contribution to journalArticle

@article{9ea6124030a746caa457356e7815c718,
title = "Clinical evaluation and applications of the Amplicor HBV Monitor(TM) test, a quantitative HBV DNA PCR assay",
abstract = "Viral load has emerged recently as a reliable marker of disease progression and therapeutic efficacy in chronic infections, including AIDS and hepatitis C. The clinical management of type B hepatitis could also be improved by monitoring viremia levels in patients with chronic liver disease undergoing anti-viral treatment. To address this question we evaluated the performance of a newly developed, quantitative PCR assay (Amplicor HBV Monitor(TM) test, Roche Diagnostic Systems) in the assessment of viremia changes over time in a group of 45 patients with chronic active hepatitis (CAH) who received interferon treatment. Of the 45 patients, 14 were HBsAg and anti-HBeAg positive and 31 HBsAg, HBeAg positive. Follow-up extended up to 24 months. An average of ten samples per patient were analyzed for levels of ALT, IgM anti-HBc (Abbott Laboratories), HBV DNA by in-house dot-blot hybridization and hybridization-capture assays (HBV-DNA hybrid capture kit, Murex Diagnostics) and by Amplicor HBV Monitor. A sustained biochemical response was observed at the end of treatment in 12 HBeAg-positive and in seven anti-HBeAg positive patients. This was accompanied by the disappearance of HBeAg and of HBV DNA (hybridization assays) in all cases and by the clearance of IgM anti-HBc in 70{\%} of the cases. Viremia (quantitative PCR assay) became undetectable only in 25-30{\%} of cases and was associated with the loss of HBsAg. A good correlation was observed between the time course of IgM anti-HBc, quantitative PCR and dot-blot hybridization although the latter missed 33{\%} of viremic samples. Together, these results indicate that the Amplicor HBV Monitor test is a robust and standardized assay for quantifying HBV viremia levels in the range from 102 to 107 copies/ml. Compared to other current markers, viral load may provide additional clinical information by predicting long term virologic response and HBsAg clearance in patients with normal ALT at the end of interferon therapy. Copyright (C) 1998 Elsevier Science B.V.",
keywords = "HBV DNA, PCR, Quantitation, Viremia",
author = "G. Gerken and J. Gomes and P. Lampertico and M. Colombo and T. Rothaar and M. Trippler and G. Colucci",
year = "1998",
month = "10",
doi = "10.1016/S0166-0934(98)00081-0",
language = "English",
volume = "74",
pages = "155--165",
journal = "Journal of Virological Methods",
issn = "0166-0934",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Clinical evaluation and applications of the Amplicor HBV Monitor(TM) test, a quantitative HBV DNA PCR assay

AU - Gerken, G.

AU - Gomes, J.

AU - Lampertico, P.

AU - Colombo, M.

AU - Rothaar, T.

AU - Trippler, M.

AU - Colucci, G.

PY - 1998/10

Y1 - 1998/10

N2 - Viral load has emerged recently as a reliable marker of disease progression and therapeutic efficacy in chronic infections, including AIDS and hepatitis C. The clinical management of type B hepatitis could also be improved by monitoring viremia levels in patients with chronic liver disease undergoing anti-viral treatment. To address this question we evaluated the performance of a newly developed, quantitative PCR assay (Amplicor HBV Monitor(TM) test, Roche Diagnostic Systems) in the assessment of viremia changes over time in a group of 45 patients with chronic active hepatitis (CAH) who received interferon treatment. Of the 45 patients, 14 were HBsAg and anti-HBeAg positive and 31 HBsAg, HBeAg positive. Follow-up extended up to 24 months. An average of ten samples per patient were analyzed for levels of ALT, IgM anti-HBc (Abbott Laboratories), HBV DNA by in-house dot-blot hybridization and hybridization-capture assays (HBV-DNA hybrid capture kit, Murex Diagnostics) and by Amplicor HBV Monitor. A sustained biochemical response was observed at the end of treatment in 12 HBeAg-positive and in seven anti-HBeAg positive patients. This was accompanied by the disappearance of HBeAg and of HBV DNA (hybridization assays) in all cases and by the clearance of IgM anti-HBc in 70% of the cases. Viremia (quantitative PCR assay) became undetectable only in 25-30% of cases and was associated with the loss of HBsAg. A good correlation was observed between the time course of IgM anti-HBc, quantitative PCR and dot-blot hybridization although the latter missed 33% of viremic samples. Together, these results indicate that the Amplicor HBV Monitor test is a robust and standardized assay for quantifying HBV viremia levels in the range from 102 to 107 copies/ml. Compared to other current markers, viral load may provide additional clinical information by predicting long term virologic response and HBsAg clearance in patients with normal ALT at the end of interferon therapy. Copyright (C) 1998 Elsevier Science B.V.

AB - Viral load has emerged recently as a reliable marker of disease progression and therapeutic efficacy in chronic infections, including AIDS and hepatitis C. The clinical management of type B hepatitis could also be improved by monitoring viremia levels in patients with chronic liver disease undergoing anti-viral treatment. To address this question we evaluated the performance of a newly developed, quantitative PCR assay (Amplicor HBV Monitor(TM) test, Roche Diagnostic Systems) in the assessment of viremia changes over time in a group of 45 patients with chronic active hepatitis (CAH) who received interferon treatment. Of the 45 patients, 14 were HBsAg and anti-HBeAg positive and 31 HBsAg, HBeAg positive. Follow-up extended up to 24 months. An average of ten samples per patient were analyzed for levels of ALT, IgM anti-HBc (Abbott Laboratories), HBV DNA by in-house dot-blot hybridization and hybridization-capture assays (HBV-DNA hybrid capture kit, Murex Diagnostics) and by Amplicor HBV Monitor. A sustained biochemical response was observed at the end of treatment in 12 HBeAg-positive and in seven anti-HBeAg positive patients. This was accompanied by the disappearance of HBeAg and of HBV DNA (hybridization assays) in all cases and by the clearance of IgM anti-HBc in 70% of the cases. Viremia (quantitative PCR assay) became undetectable only in 25-30% of cases and was associated with the loss of HBsAg. A good correlation was observed between the time course of IgM anti-HBc, quantitative PCR and dot-blot hybridization although the latter missed 33% of viremic samples. Together, these results indicate that the Amplicor HBV Monitor test is a robust and standardized assay for quantifying HBV viremia levels in the range from 102 to 107 copies/ml. Compared to other current markers, viral load may provide additional clinical information by predicting long term virologic response and HBsAg clearance in patients with normal ALT at the end of interferon therapy. Copyright (C) 1998 Elsevier Science B.V.

KW - HBV DNA

KW - PCR

KW - Quantitation

KW - Viremia

UR - http://www.scopus.com/inward/record.url?scp=0032193013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032193013&partnerID=8YFLogxK

U2 - 10.1016/S0166-0934(98)00081-0

DO - 10.1016/S0166-0934(98)00081-0

M3 - Article

VL - 74

SP - 155

EP - 165

JO - Journal of Virological Methods

JF - Journal of Virological Methods

SN - 0166-0934

IS - 2

ER -